Acutaas Chemicals ends FY26 with record margins, and doubles down on three growth engines

Acutaas Chemicals Limited, formerly known as Ami Organics, closed FY26 with a sharp improvement in profitability and a clear strategic message to investors. In Q4 FY26, revenue from operations rose to Rs. 432.8 crore, up 40.3% year on year. EBITDA grew faster than revenue, reaching Rs. 183.5 crore (up 116.0%), and PAT came in at Rs. 134.3 crore (up 114.1%). The quarter also delivered the company’s highest ever quarterly PAT margin of 31.0%.

For the full year, Acutaas reported revenue from operations of Rs. 1,339.4 crore (up 33.0%), EBITDA of Rs. 480.4 crore (up 107.0%), and PAT of Rs. 356.4 crore (up 122.2%). FY26 EBITDA margin expanded to 35.9% and PAT margin to 26.6%, a step change versus the prior year.

The quarter was led by Advance Intermediates, with specialty showing selective recovery

The Q4 revenue mix remained dominated by Advance Intermediates at Rs. 392.4 crore, while Specialty Chemicals contributed Rs. 40.3 crore. Management attributed the Advance Intermediates outperformance largely to strong momentum in CDMO, supported by steady non-CDMO pharma intermediates.

Specialty Chemicals grew 12.9% year on year in the quarter. Management noted that commodity chemicals saw degrowth, but this was offset by a recovery in the BFC semiconductor-linked business. On the call, management also shared segment profitability for the quarter: EBITDA margin was around 44% for the pharma business and around 29% for specialty chemicals, with the specialty margin benefiting from mix and recovery within BFC.

What changed in FY26: mix, operating leverage, and CDMO scale

The full-year numbers show that Acutaas is not only growing but also shifting its earnings profile. FY26 gross margin, as presented in the quarterly P&L table, expanded meaningfully compared to the previous year, and management attributed the improvement to product mix and cost efficiencies. The CFO added that operating leverage further supported EBITDA margin expansion.

Management also highlighted that the process of reshuffling the non-CDMO pharma portfolio was largely completed during the first nine months of FY26. According to the company, this helped improve the margin profile and supported sequential growth in the base pharma intermediates business in Q4.

The presentation also shows a sharp step-up in returns in FY26, with ROCE at 39.3% and ROE at 32.5% (as reported, adjusted for cash and certain items as per the slide note). While the documents do not provide cash flow statements, the balance sheet indicates cash and cash equivalents of Rs. 215.6 crore as of March 31, 2026.

Strategy: three verticals, built in parallel

Acutaas is positioning itself as a diversified chemicals company spanning three growth verticals: Battery Chemicals, Semiconductors, and Pharmaceutical CDMO. Management’s stated intent is to scale these in parallel to reduce reliance on any single driver and create multiple compounding engines.

Battery chemicals: commercialization underway, ramp expected through FY27

In battery chemicals, management stated it has successfully commercialized its first two products and expects two additional products to be brought to commercial scale in FY27. The company also disclosed capacity for electrolyte additives: 2,000 metric tons each for VC and FEC. Management indicated that the plant’s capacity is covered by customer contracts for the next three years.

On execution, the company said the first phase of electrolyte additive capex at Jhagadia is completed and the second phase is ongoing, expected to complete by Q1 FY27. Management refrained from giving a revenue figure for FY27, but repeatedly stated that battery chemicals should make a meaningful contribution, ramping quarter by quarter.

Semiconductors: recovery at BFC, and the Korea JV as the next step

Management described a recovery in the semiconductor-linked BFC business from Q4 onwards and indicated that new products beyond the earlier product set are expected to become a meaningful contributor in the coming year. The company also highlighted Indichem Inc., its South Korea joint venture, as a key long-term platform.

Acutaas invested Rs. 190 crore into Indichem during FY26. Management stated that Indichem’s R&D centre is already operational and samples have started going to prospective customers, with the intention of reducing time-to-market. On timelines, management said the facility should be completed in the second half of calendar year 2026, earlier than a previously mentioned start-of-2027 timeline.

CDMO: long-term contract visibility and a widening product set

In CDMO, management reiterated the presence of a long-term supply contract for ten years with its first customer. Beyond the marquee program, management stated that four additional CDMO products have been validated and supplied at scale for validation, and the next step is regulatory approvals. The company said each of these products could potentially deliver Rs. 50 to 100 crore of revenue at peak.

The company also maintained that the longer-term revenue ambition for CDMO remains intact, with management reiterating the previously communicated target of Rs. 1,000 crore revenue from CDMO by FY28.

Guidance and what to track next

For FY27, management guided for 25% revenue growth. On margins, management expects EBITDA margin to remain at levels similar to FY26, citing a broadly similar product mix even as battery chemicals scale up, due to incremental contribution from CDMO as well.

Capex commentary was also specific. The company stated FY26 capex was Rs. 195 crore, largely for Jhagadia battery chemicals, the pilot plant at Sachin, and maintenance. For FY27, management indicated around Rs. 50 crore of spillover capex (electrolyte additives and pilot plant) plus around Rs. 40 crore maintenance capex, with additional capex for the planned R&D expansion to be finalized and communicated later.

The call also flagged a key macro variable: disruptions from conflict in the Gulf region affecting feedstock supply chains, shipping schedules, and raw material prices. Management said it does not anticipate shortages impacting production continuity, but acknowledged the risk backdrop.

Takeaway

Acutaas’ FY26 print stands out for the pace of margin expansion, with EBITDA margin at 35.9% for the year and a particularly strong Q4. The strategic narrative is equally clear: build three independent growth engines across CDMO, battery chemicals, and semiconductors, with visible execution milestones already underway in battery chemicals and an active investment cycle in the Korea JV.

For FY27, the central questions are execution and conversion: whether the electrolyte additive ramp delivers the expected meaningful contribution, whether the additional CDMO products clear regulatory approvals and start scaling, and whether Indichem’s commissioning in 2H CY26 proceeds as guided. Management’s 25% growth guidance and expectation of similar FY26-level margins set a high bar, and the year ahead will largely be about delivering on that operating plan.